Ginkgo Bioworks (DNA) Set to Release Quarterly Earnings on Thursday

Key Points

• Ginkgo Bioworks is expected to report Q3 2026 results before Thursday’s market open. Analysts forecast a loss of $0.58 per share and revenue of $21.50 million; the earnings call is scheduled for 4:30 p.m. ET.
• The company reported a Q2 loss of $0.75 per share, beating expectations, but revenue of $20.16 million fell short of forecasts. Analysts project full-year and next-year losses of $3.20 and $2.90 per share, respectively.
• Despite shares recently trading up 18.3%, analyst sentiment remains cautious, with a consensus “Reduce” rating and average price target of $7.00 versus the reported share price of $13.34.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Ginkgo Bioworks to announce earnings of ($0.58) per share and revenue of $21.50 million for the quarter. Investors can check the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.75) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.15. The business had revenue of $20.16 million during the quarter, compared to the consensus estimate of $24.05 million. Ginkgo Bioworks had a negative return on equity of 60.27% and a negative net margin of 259.96%. On average, analysts expect Ginkgo Bioworks to post ($3.20) EPS for the current fiscal year and ($2.90) EPS for the next fiscal year.

Ginkgo Bioworks Trading Up 18.3%

Shares of NYSE:DNA opened at $13.34 on Thursday. The firm has a 50 day moving average of $9.36 and a 200-day moving average of $8.56. The stock has a market capitalization of $898.18 million, a PE ratio of -2.66 and a beta of 1.79. Ginkgo Bioworks has a 12 month low of $5.37 and a 12 month high of $18.22.

Wall Street Analyst Weigh In

Several research analysts have commented on DNA shares. Weiss Ratings restated a "sell (d-)" rating on shares of Ginkgo Bioworks in a research report on Thursday, October 15th. Wall Street Zen upgraded Ginkgo Bioworks from a "sell" rating to a "hold" rating in a research note on Saturday, September 26th. TD Cowen raised their target price on Ginkgo Bioworks from $9.00 to $11.00 and gave the company a "hold" rating in a report on Tuesday, October 13th. BTIG Research reiterated a "sell" rating and issued a $5.00 price target on shares of Ginkgo Bioworks in a research note on Friday, September 4th. Finally, Zacks Research raised Ginkgo Bioworks to a "hold" rating in a report on Monday, August 17th. Two equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, Ginkgo Bioworks currently has a consensus rating of "Reduce" and an average target price of $7.00.

Insider Activity

In other Ginkgo Bioworks news, insider Jason Kelly sold 45,682 shares of the company's stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $10.14, for a total value of $463,215.48. Following the sale, the insider owned 129,065 shares in the company, valued at approximately $1,308,719.10. The trade was a 26.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Barry Canton sold 22,369 shares of the company's stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $10.14, for a total value of $226,821.66. Following the completion of the sale, the insider owned 453,951 shares in the company, valued at $4,603,063.14. The trade was a 4.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 136,525 shares of company stock worth $1,379,699. 12.69% of the stock is owned by corporate insiders.

About Ginkgo Bioworks

Ginkgo Bioworks is a biotechnology company that develops and deploys biological systems for commercial and industrial applications. Its platform is designed to help customers program cells to produce a wide range of products, including pharmaceuticals, food ingredients, agricultural inputs, specialty chemicals and materials. The company combines biological engineering, automation, software and data science to design, build and test engineered organisms.

Ginkgo provides services through its cell-programming platform and biological engineering foundry, supporting activities such as genetic design, strain construction, laboratory testing and process development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.